# A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

> **NCT03593200** · PHASE2 · COMPLETED · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 4 (actual)

## Conditions studied

- PNH

## Interventions

- **DRUG:** Pegcetacoplan

## Key facts

- **NCT ID:** NCT03593200
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-16
- **Primary completion:** 2019-10-22
- **Final completion:** 2019-10-22
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03593200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03593200, "A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03593200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*